RecruitingNot ApplicableNCT07536516

Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients

Sponsor

Medical University of Vienna

Enrollment

20 participants

Start Date

Nov 28, 2025

Study Type

INTERVENTIONAL

Conditions

Diabetes Mellitus

Summary

The prevalence of diabetes is increasing, with type 2 diabetes mellitus comprising over 90% of cases. Diabetes mellitus complications, including diabetic retinopathy (DR), impose significant health burdens. GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists show promise in improving cardiovascular and kidney outcomes, but their effects on retinal microvasculature and neuroprotection remain unclear. This study investigates the impact of GLP-1RAs (semaglutide, liraglutide) and GIP/GLP-1-dual agonists (tirzepatide) on ocular blood flow and retinal function in DM patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called • Laser Speckle Flowgraphy (LSFG), a medical device called • Optical Coherence Tomography (OCT), and others for people with diabetes mellitus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICE• Laser Speckle Flowgraphy (LSFG)

Laser Speckle Flowgraphy (LSFG)

DEVICE• Optical Coherence Tomography (OCT)

• Optical Coherence Tomography (OCT)

DEVICE• Optical Coherence Tomography Angiography (OCT-A)

• Optical Coherence Tomography Angiography (OCT-A)

Locations(1)

Medical University Vienna

Vienna, State of Vienna, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07536516

Related Trials

Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin

NCT076214192 locations

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

NCT0753317574 locations